Albert Friedberg - May 29, 2024 Form 4 Insider Report for VACCINEX, INC. (VCNX)

Role
Director, 10%+ Owner
Signature
/s/ Dan Scheiner, Attorney-in-Fact for Albert D. Friedberg
Stock symbol
VCNX
Transactions as of
May 29, 2024
Transactions value $
$9,210
Form type
4
Date filed
5/31/2024, 04:31 PM
Previous filing
Apr 22, 2024
Next filing
Aug 1, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VCNX Common Stock Purchase $4.74K +957 +0.17% $4.95 562K May 29, 2024 By FCMI Parent Co. F3
transaction VCNX Common Stock Purchase $4.47K +861 +0.15% $5.20 562K May 30, 2024 By FCMI Parent Co. F3, F4
holding VCNX Common Stock 2.09K May 29, 2024 Direct
holding VCNX Common Stock 180 May 29, 2024 By Pan Atlantic Holdings Ltd. F1
holding VCNX Common Stock 16.7K May 29, 2024 By Friedberg Global-Macro Hedge Fund Ltd. F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding VCNX Warrant (Right to Buy) 103K May 29, 2024 Common Stock 103K $7.64 By FCMI Parent Co. F3
holding VCNX Warrant (Right to Buy) 118K May 29, 2024 Common Stock 118K $14.00 By FCMI Parent Co. F3
holding VCNX Warrant (Right to Buy) 214K May 29, 2024 Common Stock 214K $14.00 By FCMI Parent Co. F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Mr. Friedberg is the majority owner of Pan Atlantic Holdings Ltd. and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
F2 Mr. Friedberg possesses voting and dispositive power over the reported securities and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
F3 Mr. Friedberg is the majority owner, a director and the president of FCMI Parent Co. and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
F4 The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.17 to $5.20. The reporting persons undertake to provide Vaccinex, Inc., any security holder of Vaccinex, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.